MCID: ACT058
MIFTS: 53

Active Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Active Peptic Ulcer Disease

MalaCards integrated aliases for Active Peptic Ulcer Disease:

Name: Active Peptic Ulcer Disease 12 15
Gi Bleeding 12 15
Gastrointestinal Hemorrhage 74
Active Peptic Ulcer 74

Classifications:



External Ids:

Disease Ontology 12 DOID:749

Summaries for Active Peptic Ulcer Disease

MalaCards based summary : Active Peptic Ulcer Disease, also known as gi bleeding, is related to peptic ulcer disease and gastric antral vascular ectasia, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Active Peptic Ulcer Disease is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Selenium Micronutrient Network and Celecoxib Pathway, Pharmacodynamics. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Active Peptic Ulcer Disease

Diseases related to Active Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 30.5 ATP4A HRH2 PTGS2
2 gastric antral vascular ectasia 30.2 ATP12A ATP4A
3 duodenitis 30.2 ATP12A ATP4A
4 angiodysplasia 30.1 ACVRL1 VWF
5 esophagitis 30.1 HRH2 PTGS2
6 varicose veins 29.9 F2 VWF
7 gastric ulcer 29.6 HRH2 PTGS1 PTGS2
8 thrombophilia due to thrombin defect 29.2 F2 VWF
9 myocardial infarction 28.7 F2 PTGS1 PTGS2 VWF
10 fungal esophagitis 10.3 ATP12A ATP4A
11 diclofenac allergy 10.3 ATP12A ATP4A
12 gastroduodenal crohn's disease 10.3 ATP12A ATP4A
13 neonatal candidiasis 10.3 ATP12A ATP4A
14 squamous papillomatosis 10.3 ATP12A ATP4A
15 toxic megacolon 10.3 ATP12A ATP4A
16 gastrointestinal neuroendocrine benign tumor 10.3 ATP12A ATP4A
17 granulomatous gastritis 10.3 ATP12A ATP4A
18 esophageal candidiasis 10.3 ATP12A ATP4A
19 gastric neuroendocrine neoplasm 10.3 ATP12A ATP4A
20 acute laryngitis 10.3 ATP12A ATP4A
21 rumination disorder 10.3 ATP12A ATP4A
22 congenital disorder of deglycosylation 10.3 ATP12A ATP4A
23 bladder calculus 10.3 ATP12A ATP4A
24 capillary disease 10.3 ATP12A ATP4A
25 dyskinesia of esophagus 10.3 ATP12A ATP4A
26 hernia, hiatus 10.3 ATP12A ATP4A
27 anismus 10.3 ATP12A ATP4A
28 postsurgical hypothyroidism 10.3 ATP12A ATP4A
29 lymphocytic colitis 10.3 ATP12A ATP4A
30 esophageal atresia/tracheoesophageal fistula 10.3 ATP12A ATP4A
31 clostridium difficile colitis 10.3 ATP12A ATP4A
32 diarrhea 1, secretory chloride, congenital 10.3 ATP12A ATP4A
33 esophagitis, eosinophilic, 1 10.3 ATP12A ATP4A
34 microscopic colitis 10.3 ATP12A ATP4A
35 laryngeal tuberculosis 10.3 ATP12A ATP4A
36 eosinophilic gastritis 10.3 ATP12A ATP4A
37 chronic intestinal vascular insufficiency 10.3 ATP12A ATP4A
38 polyposis, skin pigmentation, alopecia, and fingernail changes 10.3 ATP12A ATP4A
39 jejunoileitis 10.3 ATP12A ATP4A
40 pancreatic steatorrhea 10.3 ATP12A ATP4A
41 superior mesenteric artery syndrome 10.3 ATP12A ATP4A
42 gastric lymphoma 10.3 ATP12A ATP4A
43 lower urinary tract calculus 10.3 ATP12A ATP4A
44 myopathy, x-linked, with excessive autophagy 10.3 ATP12A ATP4A
45 aspiration pneumonia 10.3 ATP12A ATP4A
46 pneumatosis cystoides intestinalis 10.3 ATP12A ATP4A
47 lateral medullary syndrome 10.3 ATP12A ATP4A
48 microinvasive gastric cancer 10.3 ATP12A ATP4A
49 osteopetrosis, autosomal recessive 3 10.3 ATP12A ATP4A
50 paine syndrome 10.3 ATP12A ATP4A

Comorbidity relations with Active Peptic Ulcer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 145)


Acquired Thrombocytopenia Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Abuse Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alzheimer Disease Anus Disease
Aortic Valve Disease 1 Ascending Colon Cancer
Atrophic Gastritis Bacteremia 2
Benign Essential Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cecal Benign Neoplasm
Cerebral Atherosclerosis Cerebrovascular Disease
Cholestasis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Failure Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Ulcer of Skin
Chylomicron Retention Disease Colon Carcinoma in Situ
Colorectal Cancer Conjunctivitis
Crohn's Disease Cystitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Descending Colon Cancer
Disseminated Intravascular Coagulation Duodenitis
Duodenum Cancer Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophageal Cancer Esophageal Candidiasis

Graphical network of the top 20 diseases related to Active Peptic Ulcer Disease:



Diseases related to Active Peptic Ulcer Disease

Symptoms & Phenotypes for Active Peptic Ulcer Disease

UMLS symptoms related to Active Peptic Ulcer Disease:


nausea and vomiting, constipation, fever, vomiting, fatigue, abdominal pain, edema, pruritus, hemoptysis, pain, headache, chest pain, diarrhea, syncope, nausea, chronic pain, sciatica, icterus, coughing, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, halitosis, digestive system symptom, pelvic pain, blood in stool

GenomeRNAi Phenotypes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

27 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.58 ACVRL1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.58 PTGS2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.58 ACVRL1 ATP12A PTGS2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.58 ACVRL1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.58 ATP12A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.58 ACVRL1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.58 ATP12A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.58 ACVRL1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.58 PTGS2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.58 ACVRL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.58 ACVRL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.58 PTGS2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.58 ACVRL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.58 ACVRL1 ATP12A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.58 ATP12A

MGI Mouse Phenotypes related to Active Peptic Ulcer Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 ACVRL1 ATP12A ATP4A F2 HRH2 PTGS1
2 hematopoietic system MP:0005397 9.63 ACVRL1 ATP4A F2 PTGS1 PTGS2 VWF
3 homeostasis/metabolism MP:0005376 9.56 ACVRL1 ATP12A ATP4A F2 HRH2 PTGS1
4 nervous system MP:0003631 9.1 ACVRL1 F2 HRH2 PTGS1 PTGS2 VWF

Drugs & Therapeutics for Active Peptic Ulcer Disease

Drugs for Active Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 524)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 3,Phase 1,Not Applicable 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 51-43-4 5816
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
4
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 1 117976-89-3 5029
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-78-2 2244
6
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
7
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
8
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 138530-94-6, 103577-45-3 9578005
9
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
10
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-86-1 3715
11
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 54678486 6691
12
Prucalopride Approved Phase 4 179474-81-8
13
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
14
Losartan Approved Phase 4 114798-26-4 3961
15
Angiotensin II Approved, Investigational Phase 4,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
16
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
17
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
19
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
22
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
23
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
24
Enoxaparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6 772
25
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
26
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
27
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
28
Metronidazole Approved Phase 4,Not Applicable 443-48-1 4173
29
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
30
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1197-18-8 5526
31
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
32
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
33
Budesonide Approved Phase 4,Phase 2,Not Applicable 51333-22-3 5281004 63006
34
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 15687-27-1 3672
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1177-87-3
37
Phenylephrine Approved Phase 4,Phase 3 59-42-7 6041
38
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-41-2 439260
39
Pseudoephedrine Approved Phase 4,Phase 3,Not Applicable 90-82-4 7028
40
Ephedrine Approved Phase 4,Phase 3,Not Applicable 299-42-3 9294
41
Oxymetazoline Approved, Investigational Phase 4,Phase 3 1491-59-4 4636
42
Phylloquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0
43 Menaquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 1182-68-9
44
Thrombin Approved, Investigational Phase 4,Phase 3,Not Applicable
45 Bemiparin Approved, Investigational Phase 4 91449-79-5
46
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
47
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
48
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6 774
49
Famotidine Approved Phase 4,Phase 3 76824-35-6 3325
50
Ceftriaxone Approved Phase 4,Not Applicable 73384-59-5 5479530 5361919

Interventional clinical trials:

(show top 50) (show all 634)
# Name Status NCT ID Phase Drugs
1 Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
2 Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT00861640 Phase 4 Intravenous Omeprazole;Oral Rabeprazole
3 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
4 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
5 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
6 A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
7 Oral vs Intravenous and Proton Pump Inhibitor (PPI)for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
8 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
9 Oral Resveratrol to Prevent Post-ERCP Pancreatitis Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
10 Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
11 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
12 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
13 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4 losartan (drug)
14 The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
15 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
16 Comparison of Enteral Versus Intravenous Potassium Supplementation Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
17 Steroids In caRdiac Surgery Trial (SIRS Trial) Unknown status NCT00427388 Phase 4 Methylprednisolone
18 The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI Unknown status NCT02835534 Phase 4 rhTNK-tPA;alteplase
19 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
20 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
21 Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis Unknown status NCT02505581 Phase 4 Extra dosage - cefuroxime (750mg) I.V;Cefuroxime 750mg oral;Metronidazole 250mg oral;Metronidazole 1,5gr Intravenous;Cefuroxime 1g Intravenous
22 Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
23 The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding Completed NCT00840008 Phase 4
24 Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding Completed NCT01006824 Phase 4
25 Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage Completed NCT02903017 Phase 4 Tranexamic acid 5%;Placebo
26 Seraseal for Endoscopic Hemostasis Completed NCT02349490 Phase 4
27 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy Completed NCT01654770 Phase 4
28 Iron Substitution After Upper Gastro-Intestinal Bleeding Completed NCT00978575 Phase 4 ferricarboxymaltose;Ferrosulfate;Placebo
29 Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy Completed NCT00164866 Phase 4 Omeprazole
30 Sup-Icu RENal (SIREN) Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
31 Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine Completed NCT00950339 Phase 4 omeprazole, 20mg twice daily;famotidine 40mg twice daily;pantoprazole 40mg once daily
32 Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease Completed NCT00683111 Phase 4 esomeprazole 20 mg daily;famotidine 40 mg daily
33 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone;ceftrioxone
34 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
35 Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding Completed NCT01806090 Phase 4 clopidogrel
36 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
37 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
38 Bowel Preparation for Inpatient Colonoscopy Completed NCT01169220 Phase 4 Go-Lytely;Go Lytely
39 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
40 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Completed NCT02504723 Phase 4 carvedilol;cyanoacrylate
41 Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
42 Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome Completed NCT00997750 Phase 4 Lornoxicam
43 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Completed NCT01896557 Phase 4 omeprazole;Ranitidine;Clopidogrel
44 Vasoactive Drugs in Real World Practice Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
45 Clopidogrel for Acute Ischaemia of Recent Onset Completed NCT02776540 Phase 4 Clopidogrel;Aspirin
46 Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial Completed NCT02053740 Phase 4 Add R-S-Y-R-T (500 mg 3 times per day) for 6 months;Routine western medicine
47 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
48 Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis Completed NCT00141102 Phase 4 Celecoxib;Diclofenac + Omeprazole
49 Nimodipine for Treating Acute Massive Cerebral Infarction Completed NCT02248233 Phase 4 Nimodipine;Saline + citicoline
50 PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES? Completed NCT01893541 Phase 4 PROPRANOLOL

Search NIH Clinical Center for Active Peptic Ulcer Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Active Peptic Ulcer Disease

Anatomical Context for Active Peptic Ulcer Disease

MalaCards organs/tissues related to Active Peptic Ulcer Disease:

42
Liver, Colon, Heart, Testes, Bone, Small Intestine, Kidney

Publications for Active Peptic Ulcer Disease

Articles related to Active Peptic Ulcer Disease:

(show top 50) (show all 461)
# Title Authors Year
1
Open-and-Shut Case: An Uncommon Cause of GI Bleeding. ( 30627916 )
2019
2
Additional GI bleeding risk with SSRIs in people with declining kidney function. ( 30705028 )
2019
3
Efficacy of the OTSC System in the treatment of GI bleeding and wall defects: a PMCF meta-analysis. ( 30957599 )
2019
4
RAAS Inhibition to Prevent GI Bleeding: Another Reason to Do the Right Thing. ( 30975294 )
2019
5
Concerns regarding the recommendations of the British Society of Gastroenterology's lower GI bleeding guidelines. ( 30996044 )
2019
6
Magnetically assisted capsule endoscopy in suspected acute upper-GI bleeding versus esophagogastroduodenoscopy in detecting focal lesions. ( 31082392 )
2019
7
Risk of GI Bleeding Highest with Rivaroxaban, Lower with Apixaban, and Lowest with PPI Cotherapy. ( 31083880 )
2019
8
A randomized controlled trial comparing efficacy of early video capsule endoscopy with standard of care in the approach to nonhematemesis GI bleeding (with videos). ( 29935143 )
2019
9
Endoscopic Therapy for Upper GI Bleeding on Antithrombotics - A Safe Option or Do Questions Remain? ( 30036644 )
2019
10
Early detection of GI bleeding: "starting the clock for the capsule drop". ( 30567684 )
2019
11
Comparison of clinical prediction tools and identification of risk factors for adverse outcomes in acute lower GI bleeding. ( 30576651 )
2019
12
A novel, duodenoscope-friendly endoscopic clip for treating massive upper-GI bleeding secondary to a Dieulafoy lesion. ( 30128389 )
2018
13
Upper GI Bleeding in Cirrhotic Patients: Which Method to Search for Helicobacter Pylori Infection? ( 29888786 )
2018
14
Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. ( 29408558 )
2018
15
Metastatic renal cell carcinoma to the small bowel: three cases of GI bleeding and a literature review. ( 29185198 )
2018
16
GI Bleeding During CF-LVAD Support: State of the Field. ( 29746258 )
2018
17
Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. ( 28148540 )
2018
18
Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. ( 28874418 )
2018
19
Life-threatening GI bleeding secondary to multiple gastric metastases from urothelial carcinoma of the renal pelvis. ( 29102733 )
2018
20
Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. ( 29158179 )
2018
21
A Novel Technique to Measure the Intensity of Abnormality on GI Bleeding Scans: Development, Initial Implementation, and Correlation With Conventional Angiography. ( 29215411 )
2018
22
Subacute Upper GI Bleeding Due To Infected Aortic Graft with Aorto-Duodenal Fistula. ( 29512003 )
2018
23
Blood urea nitrogen increase is an expected finding in nonvariceal upper GI bleeding patients with underlying moderate or severe renal disease. ( 29655440 )
2018
24
GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better? ( 29671162 )
2018
25
Non-variceal upper GI bleeding. ( 29671414 )
2018
26
Metastatic hepatocellular carcinoma of small bowel presenting as GI bleeding. ( 29908177 )
2018
27
Treatment of thrombocytopenic patients with GI bleeding. ( 29935628 )
2018
28
Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding. ( 30018830 )
2018
29
The Hemodynamic Profile of GI Bleeding in Continuous-Flow LVADs: Is it All About the Right Ventricle? ( 30076881 )
2018
30
Double-lumen duodenum with obscure overt GI bleeding. ( 30128382 )
2018
31
First UK data for CT angiography in persisting upper GI bleeding. ( 30245799 )
2018
32
GI Bleeding (Abstracts 530-567). ( 30297920 )
2018
33
GI Bleeding. ( 30297926 )
2018
34
Clinical Vignettes/Case Reports - GI Bleeding. ( 30297942 )
2018
35
Clinical Vignettes/Case Reports - GI Bleeding. ( 30315289 )
2018
36
Outcomes and Predictors of Readmissions with GI Bleeding in Patients with Left Ventricular Assist Devices. ( 30392001 )
2018
37
The utility of intravenous heparin to aid diagnosis and intervention in obscure GI bleeding. ( 30449413 )
2018
38
Chronic GI bleeding in a middle-aged woman. ( 30554158 )
2018
39
Obscure GI Bleeding Secondary to Diffuse Gastric Heterotopia in the Proximal Jejunum. ( 30562310 )
2018
40
Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding. ( 30598973 )
2018
41
Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy. ( 30612959 )
2018
42
EUS-guided arterial embolization with cyanoacrylate glue of a pancreatic neuroendocrine tumor infiltrating the gastric wall causing upper GI bleeding. ( 29905271 )
2017
43
Can Nonvalidated Lower GI Bleeding Predictive Scores be Evaluated by Receiver Operator Characteristics? ( 27253465 )
2017
44
Pharmacologic provocation combined with endoscopy in refractory cases of GI bleeding. ( 27343413 )
2017
45
Foiled by coils: upper GI bleeding from a rare delayed adverse event of transarterial embolization. ( 27443967 )
2017
46
Timing of upper endoscopy influences outcomes in patients with acute nonvariceal upper GI bleeding. ( 27693643 )
2017
47
Thinking out of the Gut: a case of obscure lower GI bleeding. ( 27965282 )
2017
48
A rare cause of GI bleeding in a 56-year-old man. ( 27998985 )
2017
49
Association of prophylactic endotracheal intubation in critically ill patients with upper GI bleeding and cardiopulmonary unplanned events. ( 28011279 )
2017
50
Negative result of capsule endoscopy in obscure GI bleeding: searching in the dark despite bright lights. ( 28089030 )
2017

Variations for Active Peptic Ulcer Disease

Expression for Active Peptic Ulcer Disease

Search GEO for disease gene expression data for Active Peptic Ulcer Disease.

Pathways for Active Peptic Ulcer Disease

GO Terms for Active Peptic Ulcer Disease

Biological processes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 hemostasis GO:0007599 9.52 F2 VWF
2 potassium ion import across plasma membrane GO:1990573 9.51 ATP12A ATP4A
3 positive regulation of vasoconstriction GO:0045907 9.49 HRH2 PTGS2
4 ATP hydrolysis coupled proton transport GO:0015991 9.48 ATP12A ATP4A
5 prostaglandin metabolic process GO:0006693 9.46 PTGS1 PTGS2
6 blood coagulation, intrinsic pathway GO:0007597 9.43 F2 VWF
7 cellular sodium ion homeostasis GO:0006883 9.4 ATP12A ATP4A
8 prostaglandin biosynthetic process GO:0001516 9.37 PTGS1 PTGS2
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
10 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
11 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
12 cyclooxygenase pathway GO:0019371 8.96 PTGS1 PTGS2
13 regulation of blood pressure GO:0008217 8.8 ACVRL1 PTGS1 PTGS2

Molecular functions related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 9.26 PTGS1 PTGS2
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Active Peptic Ulcer Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....